Chen Fengshi, Sato Kiyoshi, Fujinaga Takuji, Sonobe Makoto, Shoji Tsuyoshi, Sakai Hiroaki, Miyahara Ryo, Bando Toru, Okubo Kenichi, Hirata Toshiki, Date Hiroshi
Department of Thoracic Surgery, Kyoto University, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.
World J Surg. 2008 Oct;32(10):2213-7. doi: 10.1007/s00268-008-9684-8.
Pulmonary metastasectomy has become the standard therapy for various metastatic malignancies to the lungs; however, few data have been available about lung metastasectomy for hepatocellular carcinoma. To confirm the role for resection of pulmonary metastases for such tumors, we reviewed our institutional experience.
Between 1993 and 2005, 12 patients with pulmonary metastases from hepatocellular carcinomas underwent complete pulmonary resection. All patients had undergone curative resection of their primary hepatocellular carcinomas and also had obtained or had obtainable locoregional control of their primaries. Various perioperative variables were investigated retrospectively to analyze the possible prognostic factors for overall survival and pulmonary metastases-free survival after pulmonary metastasectomy.
Nine patients were male and three were female (median age, 53 (range, 43-80) years). Overall survival rate after metastasectomy was 80.8%, 57.7%, and 28.9% at 1, 2, and 5 years, respectively. Pulmonary metastases-free survival rate was 64.2%, 32.1%, and 21.4% at 1, 2, and 5 years, respectively. Five patients presented recurrences in the remaining liver before pulmonary metastases, but hepatic recurrences at this interval did not affect an overall survival after pulmonary metastasectomies. Two patients had undergone living-related liver transplantation. The maximum tumor size of the pulmonary metastasis < 3 cm was the only favorable prognostic factor for overall survival (P = 0.0006), whereas there was no significant prognostic factor for pulmonary metastases-free survival.
Pulmonary metastasectomy for hepatocellular carcinoma in selected patients was well justified when the maximum tumor size was <3 cm.
肺转移瘤切除术已成为治疗各种肺部转移性恶性肿瘤的标准疗法;然而,关于肝细胞癌肺转移瘤切除术的数据却很少。为了明确此类肿瘤肺转移瘤切除术的作用,我们回顾了我们机构的经验。
1993年至2005年间,12例肝细胞癌肺转移患者接受了肺转移瘤完整切除术。所有患者均已接受原发性肝细胞癌的根治性切除术,并且对其原发性肿瘤已获得或可获得局部区域控制。回顾性研究了各种围手术期变量,以分析肺转移瘤切除术后总生存和无肺转移生存的可能预后因素。
9例男性,3例女性(中位年龄53岁(范围43 - 80岁))。转移瘤切除术后1年、2年和5年的总生存率分别为80.8%、57.7%和28.9%。无肺转移生存率1年、2年和5年分别为64.2%、32.1%和21.4%。5例患者在出现肺转移之前,剩余肝脏出现复发,但在此期间的肝复发并不影响肺转移瘤切除术后的总生存。2例患者接受了活体肝移植。肺转移瘤最大直径<3 cm是总生存的唯一有利预后因素(P = 0.0006),而无肺转移生存无显著预后因素。
对于最大肿瘤直径<3 cm的特定患者,肝细胞癌肺转移瘤切除术是合理的。